2. GPCR/G Protein Neuronal Signaling
  3. Melanocortin Receptor
  4. PRAME peptide (425-433) acetate

PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

PRAME peptide (425-433) acetate

PRAME peptide (425-433) acetate Chemical Structure

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Other Forms of PRAME peptide (425-433) acetate:

PRAME peptide (425-433) acetate Related Antibodies

Top Publications Citing Use of Products

View All Melanocortin Receptor Isoform Specific Products:

View All Isoforms
MC1R MC3R MC2R MC4R MC5R

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma[1][2].

In Vitro

The average surface density of PRAME peptide (425-433) acetate on HLA-A*02:01-positive solid tumor cell lines is higher than that of other tested PRAME peptides[1].
PRAME peptide (425-433) acetate (50 µg/mL; 2-4 h) is presented on T2 cells, enabling 77 anti-PRAME pMHC Fabs to bind potently and selectively to T2 cells presenting PRAME peptide (425-433) acetate/HLA-A*02:01, with EC50 values <11 nM[1].
PRAME peptide (425-433) acetate (50 µg/mL; 2-4 h) is presented on the surface of T2 cells, enabling 37 anti-PRAME pMHC Fab fragments to exhibit TCR-like binding footprints to PRAME peptide (425-433) acetate/HLA-A*02:01[1].
PRAME peptide (425-433) acetate (72 h) can be targeted and bound by anti-PRAME peptide (425-433) acetate bispecific antibody-Fc TCE HU-08, HU-38, HU-19, and HU-58; it potently and selectively kills PRAME peptide (425-433) acetate-positive NCI-H1755 and SAOS-2 cancer cell lines, without causing off-target killing of PRAME-negative U87MG cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PRAME peptide (425-433) acetate Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: NCI-H1755 and SAOS-2
Concentration: 50 µg/mL
Incubation Time: 72 h
Result: Potently and selectively killed PRAME peptide (425-433) (acetate)-positive NCI-H1755 and SAOS-2 cancer cell lines, with EC50 values as low as 0.02 nM, and show no off-target killing of PRAME-negative U87MG cells.
In Vivo

Immunization in rats with PRAME peptide (425-433) acetate (10 μM) combined with PRAME peptide (425-433)/HLA-A*02:01 pMHC induces selective antibodies; these antibodies bind to the target pMHC complex with high affinity and exhibit extremely low off-target binding to irrelevant peptide-pMHC complexes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

993.20 (free base)

Formula

C46H80N12O12·xC2H4O2
Appearance

Solid

Color

White to light yellow

Sequence

Ser-Leu-Leu-Gln-His-Leu-Ile-Gly-Leu
Sequence Shortening

SLLQHLIGL
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PRAME peptide (425-433) acetate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PRAME peptide (425-433)Melanocortin ReceptorMC Receptormajor histocompatibility complex Isolid tumorsHLA-A*02:01bivalent T cell engager therapieslung squamous cell carcinomatriple-negative breast cancerhead and neck squamous cell carcinomadiffuse large b-cell lymphomalung adenocarcinomaPRAMEInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PRAME peptide (425-433) acetate
Cat. No.:
HY-P11280A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.